Compare TLYS & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLYS | PMN |
|---|---|---|
| Founded | 1982 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.1M | 136.2M |
| IPO Year | 2011 | 2022 |
| Metric | TLYS | PMN |
|---|---|---|
| Price | $4.20 | $14.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.00 | ★ $42.67 |
| AVG Volume (30 Days) | 134.9K | ★ 158.8K |
| Earning Date | 06-03-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.34 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.66 | N/A |
| Revenue Next Year | $1.74 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.14 | $0.29 |
| 52 Week High | $5.90 | $27.40 |
| Indicator | TLYS | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 52.16 | 49.64 |
| Support Level | $3.60 | $12.80 |
| Resistance Level | $4.59 | $14.40 |
| Average True Range (ATR) | 0.22 | 1.76 |
| MACD | 0.06 | -0.18 |
| Stochastic Oscillator | 72.15 | 34.67 |
Tilly's Inc works as a specialty retailer of casual apparel, footwear, and accessories for young men, young women, boys, and girls. It offers an unparalleled selection of relevant brands, styles, colors, sizes, and price points. It delivers branded fashion and core styles for tops, outerwear, bottoms, and dresses. It also provides backpacks, hats, sunglasses, headphones, handbags, watches, and jewelry. It markets its products under the brand names of Vans, RVCA, Adidas, Nike SB, and Hurley, among others. It operates its stores in malls, lifestyle centers, power centers, community centers, outlet centers, street-front locations, and also through e-commerce.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.